Capreomycin SulfateThird Party Manufacturing in India

Capreomycin Sulfate works by inhibiting bacterial protein synthesis within susceptible mycobacterial cells. As a polypeptide antibiotic, it targets the bacterial ribosome, binding specifically to both the 30S and 50S subunits of the 70S ribosome. This binding action disrupts the normal process of protein elongation, leading to the misreading of messenger RNA and preventing the translocation of transfer RNA. Without the ability to synthesize essential structural proteins and enzymes, the mycobacteria cannot grow or replicate, which ultimately leads to cell death. Capreomycin Sulfate is highly specific to Mycobacterium tuberculosis and shows no cross-resistance with other standard first-line antituberculosis medications, although some cross-resistance can occur with kanamycin or amikacin. It is primarily used as a second-line agent, providing a crucial therapeutic option when primary therapies fail due to drug resistance. Its parenteral administration ensures optimal bioavailability and consistent plasma levels in patients undergoing complex multi-drug resistant treatment regimens.

Therapeutic Uses

Capreomycin Sulfate is indicated for the treatment of:

• Multidrug-Resistant Tuberculosis (MDR-TB): Used as a second-line treatment in combination with other antituberculosis agents when first-line drugs are ineffective.
• Atypical Mycobacterial Infections: Treating pulmonary infections caused by Mycobacterium avium complex or other susceptible species.

Why Manufacturers Choose Capreomycin Sulfate

Capreomycin Sulfate is a critical component of national and global tuberculosis control programs. With the rising prevalence of multidrug-resistant tuberculosis strains, second-line polypeptide antibiotics are in constant and urgent demand by public health organizations, government supply agencies, and export markets. For pharmaceutical distributors, adding Capreomycin to their portfolio represents a significant opportunity to participate in government tenders and supply contracts.

Manufacturing sterile Capreomycin Sulfate powder for injection requires highly specialized containment facilities and aseptic powder filling lines to prevent contamination and maintain strict potency standards. Partnering with Celesta Healthcare for third party manufacturing guarantees access to high-quality Capreomycin vials (500mg and 1g) produced in WHO-GMP certified facilities. We support our partners with comprehensive regulatory documentation, helping them secure government supplies and meet international export standards in Commonwealth and developing nations.